All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Direct acting antiviral (DAA) therapy is associated with a high sustained virologic response (SVR) rate in patients with chronic hepatitis type C in comparison to conventional interferon (IFN) therapy. In July 2014, daclatasvir (DCV) (a NS5A inhibitor) and asunaprevir (ASV) (an NS3-4A protease inhibitor) were authorized for the treatment of chronic hepatitis or compensated cirrhosis in patients with hepatitis C virus (HCV) genotype 1 in Japan. It was reported that baseline resistance-associated substitutions (RASs) of NS3 D168, NS5A L31 and Y93 predicted the effects of DAA treatment in patients undergoing DCV/ASV combination therapy\[[@pone.0198642.ref001]\]. We previously reported that in patients without NS5A L31 or Y93 RASs and a history of protease inhibitor therapy, the virologic effect of DCV+ASV therapy was associated with the presence of NS5A Q24, L28, and/or R30 RASs and concomitant F37 and Q54 RASs before treatment\[[@pone.0198642.ref002]\].

In July, 2015, sofosbuvir (SOF) (an NS5B inhibitor) and ledipasvir (LDV) (an NS5A inhibitor) combination therapy were authorized for the treatment of chronic hepatitis or compensated cirrhosis in patients with HCV genotype 1 in Japan. An open-label phase 3 clinical trial in Japan showed that an SVR was achieved by 100% of patients \[[@pone.0198642.ref003]\]. The presence of baseline NS5A RASs did not affect the treatment outcome \[[@pone.0198642.ref004]\]. However, in the real world, some patients experience virologic failure. We therefore aimed to reveal the factors associated with virologic failure in patients treated with SOF/LDV, and to identify the baseline NS5A and NS5B RASs.

Materials and methods {#sec006}
=====================

The study population {#sec007}
--------------------

A total of 493 patients with HCV genotype 1 infection who were treated with SOF (90 mg/day) and LDV (400 mg/day; Harboni; Gilead Sciences, Tokyo, Japan) for 12 weeks were followed for an additional 12 weeks after treatment. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by Kagoshima University Hospital Clinical Research Ethics Committee (approval number: 170199). Written informed consent was obtained from each patient. The HCV RNA concentration was measured by a TaqMan PCR, which has a lower quantitation limit of 1.2 log IU/mL. The FIB4 index, a surrogate marker of liver fibrosis, was calculated based on the methods of previous studies \[[@pone.0198642.ref005]\].

The detection of HCV RASs {#sec008}
-------------------------

As described in detail previously \[[@pone.0198642.ref002]\], we investigated the viral genome sequence by direct sequencing. Total RNA was extracted from 140 μL of each serum sample using a QIAamp Viral RNA Mini Kit (QIAGEN, Tokyo, Japan). The extracted RNA was reverse-transcribed using a PrimeScript RT Reagent Kit attached Random 6 mers and Oligo dT Primer (TaKaRa Bio, Kusatsu, Japan). The target HCV genome was amplified by a nested PCR using PrimeSTAR GXL DNA Polymerase or LA Taq with GC Buffer (TaKaRa Bio). The primers used to amplify the NS5A and NS5B regions have been reported previously\[[@pone.0198642.ref006]--[@pone.0198642.ref009]\] ([S1 Table](#pone.0198642.s001){ref-type="supplementary-material"}). Reverse transcription was performed at 37°C for 15 minutes and terminated at 85°C for 5 seconds, followed by the first-round PCR over 30 cycles, with each cycle consisting of denaturation at 98°C for 10 seconds, annealing at 60°C for 15 seconds and extension at 68°C for 60 seconds. The second-round PCR was performed under the same condition. After purification with a GenElute PCR Clean-Up Kit (Sigma-Aldrich, Saint Louis, MO, USA), the nucleotide sequences of the second amplicons were determined using a BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Waltham, MA, USA) and Sanger sequencing. The sequences of the NS5A and NS5B RAS positions in the HCV gene were determined using HCV-Con1 (accession no. AJ238799) as a reference, as previously described and the package insert of Harboni^®^ \[[@pone.0198642.ref010]--[@pone.0198642.ref018]\]; specifically, 10 NS5A baseline RASs (Q24/K/H/R, L28M/V/I/T, R30Q/L/H/G/E, L31M/V/I/F, P32L, F37L/I/Y/V/W, Q54H/Y/E/L/N/S, P58S/H/Q/L/A, A92T/E/V/K/S and Y93H/N/S/C/F), and 7 NS5B baseline RASs (L159F, A207T/I, A218S, S282T, C316N/H/Y, L320F, V321A/I) were investigated. If \>20% of minor variants were detected in the virus population, it was regarded as RAS-positive.

Statistical analysis {#sec009}
--------------------

Statistical analyses were performed using the Statistical Package for Social Sciences software program (version 18, SPSS, Inc., Chicago, IL, USA). Categorical data were compared using the chi-squared test and Fisher\'s exact test, as appropriate. Continuous variables were analyzed using the Mann-Whitney U test. P values of \<0.05 were considered to indicate statistical significance. Factors associated with virologic failure were determined using a multivariable logistic regression analysis with forward selection using p\<0.15 as a cutoff for inclusion in the model. SVR was estimated in an intention-to-treat analysis.

Results {#sec010}
=======

The baseline characteristics of the patients {#sec011}
--------------------------------------------

The demographic baseline characteristics of the 493 patients are shown in [Table 1](#pone.0198642.t001){ref-type="table"}. The age of the patients ranged from 26 to 90 years (mean, 68 years). There were 295 female patients (60%) and 105 (21%) patients with cirrhosis. Thirty-one patients had previously been treated with DCV and ASV. Sixty-three patients (13%) had previously been treated for hepatocellular carcinoma (HCC).

10.1371/journal.pone.0198642.t001

###### The baseline characteristics of the patients who were treated with sofosbuvir/ledipasvir (n = 493).

![](pone.0198642.t001){#pone.0198642.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                                       IFN-free naïve (n = 462)   IFN-free retreatment (n = 31)   Total (n = 493)
  --------------------------------------------------------------------- -------------------------- ------------------------------- ---------------------
  Age, years (range)                                                    68.1±10.3 (26--90)         69.5±8.7 (54--86)               68.2±10.2 (26--90)

  Female, n (%)                                                         272 (59)                   23 (74)                         295 (60)

  Liver cirrhosis, n (%)                                                90 (20)                    15 (48)                         105 (21)

  Previously treated hepatocellular carcinoma, n (%)                    58 (13)                    5 (16)                          63 (13)

  Previous treatment\                                                   272 / 24 / 12 / 11\        0 / 0 / 0 / 0\                  272 / 24 / 12 / 11\
  Naïve / IFN / IFN+RBV / PEG-IFN / PR / PR+PI / DCV+ASV / unknown, n   / 89 / 38 / 0 / 16         /0 / 0 / 31 / 0                 / 89 / 38 / 31 / 16

  Laboratory data                                                                                                                  

  HCV-RNA, log IU/mL                                                    6.0±0.9                    6.0±0.6                         6.0±0.8

  White Blood Cell, /μL                                                 4741±1477                  4001±1231                       4695±1473

  Hemoglobin, g/dL                                                      13.6±1.5                   13.0±1.4                        13.6±1.5

  Platelet, ×10^4^/μL                                                   15.3±6.0                   12.5±6.6                        15.1±6.1

  AST, IU/L                                                             50±34                      52±23                           50±33

  ALT, IU/L                                                             47±39                      46±25                           47±38

  GGT, IU/L                                                             44±54                      42±34                           44±53

  Total bilirubin, mg/dL                                                0.9±0.4                    0.9±0.4                         0.9±0.4

  Albumin, g/dL                                                         4.1±0.4 (n = 450)          4.0±0.4 (n = 29)                4.1±0.4 (n = 479)

  α-Fetoprotein, ng/mL                                                  11.7±33.2 (n = 450)        21.3±48.0                       12.3±34.3 (n = 481)

  Fib-4 index                                                           4.23±3.33                  5.60±3.48                       4.32±3.35
  ------------------------------------------------------------------------------------------------------------------------------------------------------

IFN, interferon; RBV, ribavirin; PEG-IFN, pegylated-IFN; PR, PEG-IFN and RBV; PI, protease inhibitor; DCV+ASV, daclatasvir+asunaprevir; IL28B SNP, Interleukin 28B single nucleotide polymorphism; AST, aspartate transaminase; ALT, alanine aminotransferase; GGT, γ-glutamyltransferase. Data are shown as the mean ± SD unless otherwise indicated.

The prevalence of baseline RASs in the study population {#sec012}
-------------------------------------------------------

We investigated the prevalence of ten NS5A and seven NS5B baseline RASs in the study population ([S2 Table](#pone.0198642.s002){ref-type="supplementary-material"}). With the exception of A207, there was no significant difference in the NS5B RASs of the IFN-free treatment-naïve and IFN-free retreatment patients.

We investigated the co-existence of NS5A and NS5B RASs. Sixty of 87 patients (69.0%) had co-existing RASs of Q24, L28 or R30. Furthermore, 208 of 210 patients with NS5B C316 RAS (99.0%) had concomitant NS5B A218 and C316 RASs. In addition, 208 of 263 patients with NS5B A218 RAS (79.1%) had concomitant NS5B A218 and C316 RASs (It was not possible to detect A218 or C316 RASs in 11 patients).

The virologic response rate {#sec013}
---------------------------

Among the 462 IFN-free treatment-naïve patients who received SOF/LDF, 452 patients (97.8%) completed treatment. Overall, 95.0% of the patients (363/450) had undetectable HCV RNA levels at the fourth week of treatment and 99.8% (450/451) had undetectable HCV RNA levels at the end of treatment. An SVR at 12 weeks (SVR12) was achieved in 451 patients (97.6%) in the intention-to-treat analysis ([Fig 1](#pone.0198642.g001){ref-type="fig"}). On the other hand, among the 31 patients who received SOF+LDF therapy in IFN-free retreatment, 30 patients (96.8%) completed treatment. Overall, 63.3% of patients (19/30) had undetectable HCV RNA levels at week 4 of treatment and 100% (30/30) had undetectable HCV RNA levels at the end of treatment. An SVR12 was achieved in 25 patients (80.6%) in the intention-to-treat analysis ([Fig 1](#pone.0198642.g001){ref-type="fig"}).

![The virologic response rates (intention-to-treat analysis).\
The sustained virologic response (SVR) 12 rates of the IFN-free treatment-naïve patients and IFN-free retreatment patients were 97.6% and 80.6% respectively.](pone.0198642.g001){#pone.0198642.g001}

The RASs in patients with virologic failure {#sec014}
-------------------------------------------

Eleven (2.2%) patients (IFN-free treatment-naïve, n = 6; IFN-free retreatment, n = 5) were considered to have virologic failure ([Table 2](#pone.0198642.t002){ref-type="table"}). All patients had relapsed disease. We examined the baseline RASs of these 11 patients. Eight of 11 patients (72.7%) had NS5A Y93 RASs, 5 of 11 patients (45.5%) had NS5A Q24, L28, and/or R30 RASs, and 4 of 11 patients (36.4%) had NS5A L31 RASs. Three patients had coexisting NS5A L31 and Y93 RASs at the baseline. In brief, 8 of 11 patients (72.2%) had coexisting NS5A Q24, L28 and/or R30 RASs, L31 RAS or Y93 RAS at the baseline. One patient who underwent IFN-free retreatment and who did not have NS5A L31 or Y93 RASs, had baseline NS5A P32L and A92K RASs.

10.1371/journal.pone.0198642.t002

###### The baseline resistance-associated substitutions (RASs) and virologic failure in patients treated with sofosbuvir and ledipasvir.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Age\     Etio-\   Previous treatment\   RAS (upper row: baseline, lower: after virologic failure)                                                                      
         Gender   logy     (outcome)                                                                                                                                            
  ------ -------- -------- --------------------- ----------------------------------------------------------- --- --- ----- --- --- ----- --- --- ----- ---- --- --- --- --- --- ---
  1      62\      CH       Naïve                 K                                                           M   Q   .     .   .   H/Q   .   .   Y/H   .    T   S   .   N   .   .
         F                                                                                                                                                                      

  K      M        Q        .                     .                                                           .   .   .     .   H   .     T   S   .     N    .   .               

  2      76\      CH       PR (relapse)          K                                                           M   Q   .     .   .   .     .   .   H     .    T   S   .   N   .   .
         F                                                                                                                                                                      

  K      M        Q        .                     .                                                           .   .   .     .   H   .     T   S   .     N    .   .               

  3      70\      CH       Naïve                 .                                                           .   .   .     .   .   .     .   .   .     .    .   S   .   N   .   .
         M                                                                                                                                                                      

  .      .        .        V                     .                                                           .   .   .     .   H   .     .   S   .     N    .   .               

  4      56\      LC       Naïve                 .                                                           .   .   .     .   .   Q/H   .   .   H     ND   .   S   .   N   .   .
         F                                                                                                                                                                      

  .      .        .        M                     .                                                           .   H   .     .   H   .     .   S   .     N    .   .               

  5      74\      CH       Naïve                 Q/R                                                         .   Q   .     .   .   .     .   .   H     .    T   S   .   N   .   .
         M                                                                                                                                                                      

  .      .        Q        .                     .                                                           .   .   .     .   H   .     T   S   .     N    .   .               

  6      76\      CH       PR (null)             .                                                           .   .   M/L   .   L   .     .   .   H     ND   .   S   .   .   .   .
         M                                                                                                                                                                      

  .      .        .        M                     .                                                           L   .   .     .   H   .     .   S   .     .    .   .               

  7      57\      CH       SMV +PR(null)\        .                                                           .   .   V     .   L   H     .   .   H     .    .   S   .   .   .   .
         F                 DCV/ASV (null)                                                                                                                                       

  .      .        .        V                     .                                                           L   H   .     .   H   .     .   S   .     .    .   .               

  8      73\      CH       DCV/ASV (relapse)     .                                                           .   .   .     L   L   H     .   K   .     ND   .   S   .   N   .   .
         F                                                                                                                                                                      

  .      .        .        .                     L                                                           L   .   .     K   .   .     .   S   .     N    .   .               

  9      80\      LC       DCV/ASV (VBT)         K                                                           M   Q   .     .   .   .     .   .   H     .    T   S   .   N   .   .
         F                                                                                                                                                                      

  K      M        Q        .                     .                                                           .   .   .     .   H   .     T   S   .     N    .   .               

  10     64\      LC       DCV/ASV (null)        .                                                           .   .   V     .   .   .     .   .   H     .    T   S   .   N   .   .
         F                                                                                                                                                                      

  .      .        .        V                     .                                                           .   .   .     .   H   .     T   S   .     N    .   .               

  11     86\      CH       DCV/ASV (relapse)     .                                                           M   .   F     .   L   H     L   .   .     .    .   .   .   .   .   .
         M                                                                                                                                                                      

  .      M        .        F                     .                                                           L   H   L     .   .   .     .   .   .     .    .   .               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dots mean non-RAS amino acid.

CH, chronic hepatitis; IL28B SNP, Interleukin 28B single nucleotide polymorphism; PR, pegylated-interferon and ribavirin; LC, liver cirrhosis; SNP, single nucleotide polymorphism; ND, no data; SMV, simeprevir; DCV, daclatasvir; ASV, asunaprevir; VBT, viral breakthrough.

In the analysis of post-treatment RASs, the patients who had coexisting Q24, L28, and/or R30, L31 or Y93 RASs at the baseline showed no change in their NS5A RAS profile. However, two patients acquired NS5A L31 and Y93 RASs. The patient who had baseline NS5A P32L and A92K RASs did not acquire NS5A L31 or Y93 RASs.

We analyzed 7 NS5B RASs. Interestingly, 10 of 11 patients had an NS5B A218 RAS, 8 of 11 patients had an NS5B C316 RAS, and 5 of 11 patients had an NS5B A207 RAS at the baseline. No patients had NS5B L159, S282, L320 or V321 RASs at the baseline. In particular, the patients who had NS5B C316 RAS also had coexisting A218 RAS. In addition, no patients acquired these RASs.

Factors associated with virologic failure {#sec015}
-----------------------------------------

We analyzed the factors associated with virologic failure among the patients who completed treatment. Among the blood biochemistry data, significant differences were observed in the platelet count and γ- glutamyltransferase (GGT) levels between the SVR12 and no-SVR12 groups; however, there were no differences between the IFN-free treatment-naïve and IFN-free retreatment groups ([S3 Table](#pone.0198642.s003){ref-type="supplementary-material"}).

[Table 3](#pone.0198642.t003){ref-type="table"} showed the SVR rates according to the various categories. A univariate analysis in all cases showed that HCV RNA ≥6.5 log IU/mL (p = 0.016), platelet count \<10×10^4^/μL (p = 0.041), and GGT ≥37IU/L (p = 0.022) were associated with an SVR12. Among the RASs of NS5A, RASs of NS5A: Q24, L28, and/or R30 (p = 0.014), L31 (p = 0.006), P32 (p\<0.001), and Y93 (p = 0.001), were associated with SVR12. In particular, coexisting NS5A RASs (Q24, L28, and/or R30, L31, or Y93 RAS) were associated with a lower SVR12 rate in comparison to no RASs or a single RAS. Interestingly, among the RASs of NS5B, RASs of A218 (p = 0.013) and C316 (p = 0.042) were associated with an SVR12. Similarly, NS5B A218 and/or C316 were significantly associated with an SVR12 (p = 0.015).

10.1371/journal.pone.0198642.t003

###### The SVR12 rates of patients treated with ledipasvir and sofosbuvir.

![](pone.0198642.t003){#pone.0198642.t003g}

  Category                                                        Cut off             IFN-free naïve (n = 452)   IFN-free retreatment (n = 30)   Overall (n = 482)                                     
  --------------------------------------------------------------- ------------------- -------------------------- ------------------------------- ------------------- ----- ------ ------- ----- ------ ---------
  Age                                                             \<75                321                        98.8                            0.813               20    85.0   0.729   341   97.9   0.600
  ≥75                                                             131                 98.5                       10                              80.0                141   97.2                        
  Gender                                                          Male                187                        98.4                            0.666               7     85.7   0.847   194   97.9   0.790
  Female                                                          265                 98.9                       23                              82.6                288   95.6                        
  Etiology                                                        CH                  365                        98.6                            0.872               16    81.3   0.743   381   97.9   0.602
  LC                                                              87                  98.9                       14                              85.7                101   97.0                        
  Previously treated HCC                                          No                  397                        98.5                            0.359               25    80.0   0.273   422   97.4   0.206
  Yes                                                             55                  100                        5                               100                 60    100                         
  HCV-RNA                                                         \<6.5 logIU/mL      314                        99.0                            0.297               21    95.2   0.008   335   98.8   0.016
  ≥6.5 logIU/mL                                                   138                 97.8                       9                               55.6                147   95.2                        
  Platelet                                                        \< 10.0 ×10^4^/μL   86                         97.7                            0.369               14    78.6   0.513   100   95.0   0.041
  ≥10.0 ×10^4^/μL                                                 366                 98.9                       16                              87.5                382   98.4                        
  GGT                                                             \<37                272                        99.6                            0.028               20    90.0   0.166   426   98.4   0.022
  ≥37                                                             180                 97.2                       10                              70.0                56    92.9                        
  Fib4-index                                                      \<6.55              383                        99.0                            0.215               20    85.0   0.729   403   98.3   0.070
  ≥6.55                                                           69                  97.1                       10                              80.0                79    94.9                        
  NS5A:Q24, L28, and/or R30 RAS                                   No                  375                        99.2                            0.023               18    83.3   1.000   393   98.5   0.014
  Yes                                                             72                  95.8                       12                              83.3                84    94.0                        
  NS5A:L31 RAS                                                    No                  411                        98.8                            0.435               14    85.7   0.743   425   98.4   0.006
  Yes                                                             36                  97.2                       16                              81.3                52    92.3                        
  NS5A:P32 RAS                                                    No                  446                        98.7                            0.907               28    85.7   0.190   474   97.9   \<0.001
  Yes                                                             1                   100                        2                               50.0                3     66.7                        
  NS5A:F37 RAS                                                    No                  212                        97.6                            0.076               15    86.7   0.624   227   96.9   0.281
  Yes                                                             235                 99.6                       15                              80.0                250   98.4                        
  NS5A:Q54 RAS                                                    No                  242                        98.3                            0.535               12    83.3   1.000   254   97.6   0.931
  Yes                                                             205                 99.0                       18                              83.3                223   97.8                        
  NS5A:P58 RAS                                                    No                  415                        98.6                            0.493               27    85.2   0.414   442   97.7   0.821
  Yes                                                             32                  100                        3                               66.7                35    97.1                        
  NS5A:A92 RAS                                                    No                  413                        98.5                            0.479               26    84.6   0.631   439   97.7   0.889
  Yes                                                             34                  100                        4                               75.0                38    97.4                        
  NS5A:Y93 RAS                                                    No                  326                        99.7                            0.002               13    84.6   0.869   339   99.1   0.001
  Yes                                                             122                 95.9                       17                              82.4                139   94.2                        
  The number of NS5A RASs[^†^](#t003fn002){ref-type="table-fn"}   0                   251                        99.6                            \<0.001             5     80.0   0.399   256   99.2   \<0.001
  1                                                               161                 99.4                       7                               100                 168   99.4                        
  ≥2                                                              34                  88.2                       18                              77.8                52    84.6                        
  NS5B:L159 RAS                                                   No                  413                        99.0                            0.843               25    80.8   0.664   438   98.2   0.760
  Yes                                                             4                   100                        1                               100                 5     100                         
  NS5B:A207 RAS                                                   No                  328                        99.1                            0.184               16    81.3   0.811   344   98.3   0.175
  Yes                                                             117                 97.4                       13                              84.6                130   96.2                        
  NS5B:A218 RAS                                                   No                  208                        100                             0.021               9     88.9   0.558   217   99.5   0.013
  Yes                                                             237                 97.5                       20                              80.0                257   96.1                        
  NS5B:S282 RAS                                                   No                  443                        98.6                                                29    82.8           472   97.7   
  Yes                                                             0                   0                          0                               0                   0     0                           
  NS5B:C316 RAS                                                   No                  257                        99.6                            0.039               13    84.6   0.811   270   98.9   0.042
  Yes                                                             186                 97.3                       16                              81.3                202   96.0                        
  NS5B:L320 RAS                                                   No                  443                        98.6                                                29    82.8           472   97.7   
  Yes                                                             0                   0                          0                               0                   0     0                           
  NS5B:V321 RAS                                                   No                  438                        98.6                            0.792               29    82.8           467   97.6   0.728
  Yes                                                             5                   100                        0                               0                   5     100                         
  NS5B:A218 and/or C316 RASs                                      No                  201                        100                             0.023               9     88.9   0.558   210   99.5   0.015
  Yes                                                             235                 97.4                       20                              80.0                255   96.1                        

CH, chronic hepatitis; LC, liver cirrhosis; IL28B SNP, Interleukin 28B single nucleotide polymorphism; GGT, γ-glutamyltransferase; HCC, hepatocellular carcinoma; RAS, resistance-associated substitution.

^t†^ The number of NS5A RASs indicates the sum of Q24, L28, and/or R30 RAS, L31 RAS,and Y93 RAS.

Among the demographic parameters in the IFN-free treatment-naïve, RASs of NS5A Q24, L28, and/or R30 (p = 0.023), Y93 (p = 0.002), NS5B: A218 (p = 0.021) and C316 (p = 0.039) were associated with an SVR12. Similarly, coexisting NS5A RASs (Q24, L28, and/or R30, L31, or Y93 RAS) and NS5B RAS (A218 and/or C316) were associated with a lower SVR12 rate in comparison to no RASs or a single RAS. On the other hand, among the demographic parameters in the IFN-free retreatment group, IL28B SNP (p = 0.016), and HCV RNA ≥6.5 log IU/mL (p = 0.008), were associated with an SVR12; however, RASs of NS5A, and NS5B, were not associated with an SVR12.

Many patients with virologic failure had coexisting NS5A or NS5B RASs, we conducted a multivariable logistic regression analysis considering the coexistence of NS5A or NS5B RASs. More than 2 NS5A RASs (odds ratio \[OR\], 42.297; 95% confidence interval \[CI\], 6.250--286.241), NS5A P32 RAS (OR, 36.725; CI, 1.603--841.157), NS5B A218 and/or C316 RAS (OR, 19.377; CI, 1.597--235.071), and GGT ≥37IU/L (OR, 11.573; CI, 2.151--62.270) were also associated with virologic failure ([Table 4](#pone.0198642.t004){ref-type="table"}).

10.1371/journal.pone.0198642.t004

###### The multivariate logistic regression analysis of factors associated with virologic failure in patients treated with sofosbuvir and ledipasvir.
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  Category                                                       Cut off         Univariate   Multivariate                                         
  -------------------------------------------------------------- --------------- ------------ ---------------- --------- -------- ---------------- ---------
  Age                                                            ≥75 years       1.393        0.401--4.836     0.600                               
  Gender                                                         Female          1.183        0.342--4.098     0.790                               
  HCV RNA                                                        ≥6.5 logIU/mL   4.138        1.192--14.359    0.016                               
  Platelet                                                       \<10×10^4^/μL   3.298        0.986--11.038    0.041                               
  GGT                                                            ≥37 IU/L        4.234        1.109--16.168    0.022     11.573   2.151--62.270    0.004
  Fib-4 index                                                    ≥6.55           3.017        0.862--10.563    0.070                               
  The number of NS5A RAS[^†^](#t004fn002){ref-type="table-fn"}   ≥2RASs          32.211       6.789--152.831   \<0.001   42.297   6.250--286.241   \<0.001
  NS5A: P32 RAS                                                  Yes             23.200       1.941--277.273   \<0.001   36.725   1.603--841.157   0.024
  NS5B:A207 RAS                                                  Yes             2.253        0.676--7.514     0.175     0.306    0.057--1.643     0.167
  NS5B:A218 and/or C316 RAS                                      Yes             8.531        1.083--67.192    0.013     19.377   1.597--235.071   0.020
  IFN free therapy                                               retreatment     14.867       4.245--52.062    \<0.001   3.017    0.590--15.425    0.185

OR, odds ratio; CI, confidence interval; IL28B SNP, Interleukin 28B single nucleotide polymorphism; GGT, γ-glutamyltransferase; RAS resistance-associated substitution; IFN, interferon

^†^The number of NS5A RASs indicates the sum of Q24, L28, and/or R30 RAS, L31 RAS, and Y93 RAS.

SVR12 rate in patients with coexisting NS5A and NS5B RASs {#sec016}
---------------------------------------------------------

We analyzed the SVR12 rate in patients with coexisting NS5A and NS5B RASs. Among the IFN-free treatment-naïve patients, all of the patients without NS5B A218 and/or C316 RASs achieved an SVR12 ([Fig 2](#pone.0198642.g002){ref-type="fig"}). In particular, the SVR12 rate of the patients who had more than two NS5A RASs (Q24, L28 and/or R30 RAS, L31 RAS, or Y93 RAS) and NS5B A218 and/or C316 RASs was 83.3%. On the other hand, in the IFN-free retreatment patients, all patients with virologic failure had coexisting NS5A RASs (Q24, L28 and/or R30 RAS, L31 RAS, or Y93 RAS) with the exception of one case that had NS5A P32L and A92K RASs; however these RASs did not have a significant difference on the SVR12 rate.

![The sustained virologic response (SVR) 12 rate in the patients with co-existing NS5A and NS5B RASs.\
The interferon (IFN) free-naïve patients with coexisting resistance-associated substitutions (RASs) of Q24, L28, and/or R30, L31, or Y93 and NS5B A218 and/or C316 had a significantly lower sustained virologic response (SVR) 12 rate in comparison to the patients without these RASs.](pone.0198642.g002){#pone.0198642.g002}

Discontinuation of therapy {#sec017}
--------------------------

Eleven patients (2.2%) discontinued SOF/LDV therapy ([Table 5](#pone.0198642.t005){ref-type="table"}). All patients were \>65 years of age. Three patients discontinued therapy due to fatigue, and 2 patients each discontinued therapy due to renal injury or skin itching. Five patients discontinued therapy due to other reasons (hyperbilirubinemia, diarrhea, brain hemorrhage, and unknown). The mean time to discontinuation was 4.5 weeks. All patients receiving SOF/LDV for more than 8 weeks achieved an SVR12.

10.1371/journal.pone.0198642.t005

###### The reasons for the discontinuation of sofosbuvir/lediprevir.

![](pone.0198642.t005){#pone.0198642.t005g}

  --------------------------------------------------------------------------------------------------------------------------------------
  case   Age\     Etiology   Previous treatment\   Previously treated\   Discontinued weeks   Reason of discontinued therapy   outcome
         gender                                    HCC                                                                         
  ------ -------- ---------- --------------------- --------------------- -------------------- -------------------------------- ---------
  1      77M      CH         Naïve                 No                    10                   Unknown                          SVR24

  2      66M      CH         SMV+PR                No                    9                    Skin Itching                     SVR24

  3      90F      CH         Naïve                 No                    8                    Skin Itching                     SVR24

  4      68M      LC         PR                    No                    8                    Depression, fatigue              SVR24

  5      78F      LC         Naïve                 Yes                   5                    Brain hemorrhage                 Relapse

  6      79F      CH         Naïve                 Yes                   4                    Renal injury                     SVR24

  7      74M      LC         DCV/ASV               No                    2                    Renal injury                     Non-SVR

  8      76F      CH         Naïve                 No                    1                    Fatigue                          Non-SVR

  9      74F      LC         IFN+RBV               No                    1                    Hyperbilirubinemia               Non-SVR

  10     72F      CH         IFN                   Yes                   1                    Diarrhea                         Non-SVR

  11     77F      CH         Naïve                 No                    1                    Fatigue                          Non-SVR
  --------------------------------------------------------------------------------------------------------------------------------------

HCC, hepatocellular carcinoma; CH, chronic hepatitis; SVR, sustained virologic response; SMV, simeprevir; PR, pegylated interferon and ribavirin; LC, liver cirrhosis; DCV, daclatasvir; ASV, asunaprevir; IFN, interferon; RBV, ribavirin.

Discussion {#sec018}
==========

We revealed, for the first time, that most SOF/LDV-treated patients with virologic failure had RASs of NS5B A218 and/or C316, and these RAS was significantly associated with virologic failure. Donaldson et al. reported that NS5B C316 was associated with virologic failure \[[@pone.0198642.ref017]\]; however while many studies have reported the analysis of large study populations \[[@pone.0198642.ref019]--[@pone.0198642.ref025]\], no reports have indicated that NS5B A218 RAS is associated with virologic failure in SOF/LDV-treated patients. The reason why we paid attention to NS5B A218 and/or C316 RAS was that 8 of the 11 patients with virologic failure had coexisting NS5B A218 and C316 RAS ([Table 2](#pone.0198642.t002){ref-type="table"}). In addition, NS5B A218 and C316 showed a high rate of coexistence at baseline. Iio et al. showed a similar report about the coexistence of NS5B A218 and C316 in patients with virologic failure \[[@pone.0198642.ref019]\]. Donaldson et al. reported that NS5B C316N may interfere with the ability of SOF to enter the active site by blocking the space \[[@pone.0198642.ref017]\]; thus, these RASs might have inhibited the activity of SOF cooperatively.

The prevalence of NS5B A218 in the IFN-free treatment-naïve and IFN-free retreatment patients in this cohort was 53.6% (244/455) and 70.0% (21/30) respectively ([S2 Table](#pone.0198642.s002){ref-type="supplementary-material"}). Further, the prevalence of NS5B C316 in the IFN-free treatment-naïve and IFN-free retreatment patients in this cohort was 42.7% (193/452) and 56.7% (17/30) respectively ([S2 Table](#pone.0198642.s002){ref-type="supplementary-material"}). Ito et al. reported that the prevalence of NS5B C316N in 96 Japanese patients was 46.9% \[[@pone.0198642.ref009]\]. However, no studies have reported the prevalence of NS5B A218 RAS. Especially, 99.0% of patients who had NS5B C316 RAS had coexisting A218 RAS. The prevalence needs to be confirmed in other populations.

SOF is a nucleotide inhibitor directed at the activity of NS5B, the protein of which is essential for HCV replication. SOF, which prevents HCV RNA synthesis by acting as a "chain terminator", has broader genotype coverage and a higher barrier to viral resistance \[[@pone.0198642.ref013]\]. Some clinical researchers reported that RASs of NS5B L159, S282, C316, L320, or V321 were associated with virologic failure \[[@pone.0198642.ref014], [@pone.0198642.ref015], [@pone.0198642.ref017]\]. However, with the exception of S282, these RASs were associated with low-level resistance in the replicon systems \[[@pone.0198642.ref013], [@pone.0198642.ref014], [@pone.0198642.ref016], [@pone.0198642.ref026]\]. In this cohort, no cases had RASs of S282, L320 before treatment or at the time that treatment was deemed unsuccessful, and all of the cases with RASs of L159 and V321 achieved an SVR ([Table 3](#pone.0198642.t003){ref-type="table"}). There have been no reports about the RAS of NS5B A218 or the coexistence of A218 and C316 *in vitro*. Thus, it is important to confirm the effects of SOF in cases involving the coexistence of NS5B A218 and/or C316 RASs using a replicon system or a human hepatocyte chimera mouse model as soon as possible.

SOF/LDV therapy was associated with good therapeutic outcomes, even in patients with NS5A Y93 RAS, with 100% of the patients in a phase III trial in Japan showing an SVR \[[@pone.0198642.ref003]\]. Some reports indicate that NS5A Y93 RAS is not related to the therapeutic effect \[[@pone.0198642.ref004], [@pone.0198642.ref019], [@pone.0198642.ref024]\]. The American Association for the Study of Liver Diseases/Infectious Diseases Society of America \[[@pone.0198642.ref027]\] and the European Association for the Study of the Liver guidelines \[[@pone.0198642.ref028]\] have not mentioned any need for the routine investigation of NS5A RAS. On the other hand, other reports suggest that it is related to the therapeutic effect \[[@pone.0198642.ref020], [@pone.0198642.ref021]\]. In the present study, the SVR12 rate was 97.6%; thus the routine investigation of NS5A RAS might not be necessary. However, most cases of virologic failure involved coexisting NS5A RAS, and this was related to the therapeutic effect ([Table 4](#pone.0198642.t004){ref-type="table"}). It is noteworthy that the SVR rate of the IFN free-naïve patients with a single substitution of Q24, L28, and/or R30, L31, or Y93 were significantly higher than those with more than two substitution (\>99% vs 88.2%) ([Table 3](#pone.0198642.t003){ref-type="table"}), and most cases of virologic failure involved the coexistence of these RASs ([Table 2](#pone.0198642.t002){ref-type="table"}). On the other hand, an SVR was achieved in all cases without NS5B A218 and/or C316 RASs. In contrast, the SVR12 rates of the patients who had more than two NS5A RASs and NS5B A218 and/or C316 RAS was 83.3% ([Fig 2](#pone.0198642.g002){ref-type="fig"}). It was suggested that the coexistence of NS5A and NS5B RASs was highly associated with virologic failure; thus, investigating the baseline NS5A and NS5B RAS status, is useful for in efforts to increase the SVR rate to 100%. Therefore, the existence of baseline RAS should be considered at the choice of treatment regimen in order to eradicate HCV.

Overall, HCV elimination is not achieved in 10--15% of the patients who receive DCV/ASV \[[@pone.0198642.ref001], [@pone.0198642.ref002], [@pone.0198642.ref029]\]. This represented a major problem for HCV treatment because such patients had coexisting RASs in the NS3 and NS5A regions and these RASs had cross-resistance \[[@pone.0198642.ref030]\]. Upon DCV/ASV treatment failure in human hepatocyte chimeric mice, NS5A L31V and Y93H RAS were relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor \[[@pone.0198642.ref031]\]. In previous studies, the SVR rates of IFN-free retreatment patients who received LDV/SOF (+ribavirin) were 71--86.7% \[[@pone.0198642.ref020], [@pone.0198642.ref032]--[@pone.0198642.ref034]\]. However, it was unclear which RASs were associated with virologic failure in these patients. In the present study, most patients with a single RAS of NS5A were achieved an SVR; however the result did not reach statistical significance, because of the small number of cases. Furthermore, NS5A P32 RAS was observed in 3 patients (one patient was IFN-free treatment-naïve, two patients received IFN-free retreatment). IFN-free treatment-naïve patients with NS5A P32 RAS achieved an SVR, one of two IFN-free retreatment patients showed virologic failure and had coexisting NS5A A92K RAS. These RASs were very rare; however, they have been reported to emerge after failure to respond to DCV/ASV \[[@pone.0198642.ref002], [@pone.0198642.ref029], [@pone.0198642.ref035]\]. NS5A A92K RAS is reported to have over 1000-fold resistance to LDV in comparison to the wild-type; in addition, P32L RAS have 2.5--10.0-fold resistance \[[@pone.0198642.ref026]\]. The coexistence of NS5A P32L and A92K RASs might be associated with the therapeutic effect. Meanwhile, there were no patients with NS5A P32 deletion in this cohort. In Japan, Glecaprevir/Pibrentasvir therapy was approved in September 2017, following a study in which the SVR rate in patients with DAA retreatment was 93.9%; however, two patients with virologic failure had an NS5A P32 deletion \[[@pone.0198642.ref036]\]. In the future, it is necessary to clarify the factors associated with the therapeutic effects of IFN-free retreatment patients in a large study population.

In the present study, GGT elevation was associated with virologic failure. Abe et al. reported that GGT elevation was associated with IL28B polymorphism \[[@pone.0198642.ref037]\]. The therapeutic effect of SOF/LDV might be related to host factors in IFN-free retreatment especially.

In the present study, 11 patients (2.2%) discontinued SOF/LDV therapy. In previous studies, 0--5.3% of patients who received SOF/LDV discontinued therapy \[[@pone.0198642.ref019]--[@pone.0198642.ref025]\]. All patients were \>65 years of age. Thus physicians should pay careful attention when SOF/LDV is administered to elderly patients.

The present study was associated with several limitations. First, only 11 (2.2%) of 482 patients had virologic failure; thus, the range of the 95% CI was wide, despite the fact that a statistically significant difference was observed. Second, it was not possible to detect all RASs in some cases. Third, since the number of cases was smaller than that of previous studies, a larger cohort should be analyzed in a future study.

In conclusion, SOF/LDV therapy showed a high SVR12 rate. However, the coexistence of NS5A and NS5B RASs were associated with virologic failure. These results might indicate that the coexistence of baseline RASs influence the therapeutic effects of SOF/LDV.
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